These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1283 related articles for article (PubMed ID: 32935333)

  • 1. T-cell responses and therapies against SARS-CoV-2 infection.
    Toor SM; Saleh R; Sasidharan Nair V; Taha RZ; Elkord E
    Immunology; 2021 Jan; 162(1):30-43. PubMed ID: 32935333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets.
    Ruenjaiman V; Hirankarn N; Palaga T
    Asian Pac J Allergy Immunol; 2021 Jun; 39(2):69-77. PubMed ID: 34174806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging roles of extracellular vesicles in COVID-19, a double-edged sword?
    Xia X; Yuan P; Liu Y; Wang Y; Cao W; Zheng JC
    Immunology; 2021 Aug; 163(4):416-430. PubMed ID: 33742451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypes and Functions of SARS-CoV-2-Reactive T Cells.
    Jung MK; Shin EC
    Mol Cells; 2021 Jun; 44(6):401-407. PubMed ID: 34120892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.
    Marian AJ
    Cardiovasc Pathol; 2021; 50():107278. PubMed ID: 32889088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.
    Shah P; Canziani GA; Carter EP; Chaiken I
    Front Immunol; 2021; 12():637651. PubMed ID: 33767706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
    Egilmezer E; Rawlinson WD
    Rev Med Virol; 2021 Nov; 31(6):e2227. PubMed ID: 33763936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS coronavirus 2: from genome to infectome.
    Rastogi M; Pandey N; Shukla A; Singh SK
    Respir Res; 2020 Dec; 21(1):318. PubMed ID: 33261606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
    Majumder J; Minko T
    AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions.
    Shah M; Woo HG
    Mol Cells; 2021 Jun; 44(6):408-421. PubMed ID: 34059561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An
    Pechous RD; Malaviarachchi PA; Banerjee SK; Byrum SD; Alkam DH; Ghaffarieh A; Kurten RC; Kennedy JL; Zhang X
    J Virol; 2024 Jul; 98(7):e0079424. PubMed ID: 38940558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
    Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
    Borges RC; Hohmann MS; Borghi SM
    Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The T cell immune response against SARS-CoV-2.
    Moss P
    Nat Immunol; 2022 Feb; 23(2):186-193. PubMed ID: 35105982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.
    Ghasemzadeh M; Ghasemzadeh A; Hosseini E
    Hum Immunol; 2022 Jan; 83(1):86-98. PubMed ID: 34583856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
    Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
    Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).
    Andrew M; Jayaraman G
    Carbohydr Res; 2021 Jul; 505():108326. PubMed ID: 34015720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.